Makes MRI scanners that can guide surgeons in real time while the magnet stays on.
At a glance
- Depends onDownstream position: depends on 8 industries, supplies 3
- ScaleRevenue is in the top 5% of all stocks globally
Makes MRI scanners that can guide surgeons in real time while the magnet stays on.
What this company is and how it runs — written from structure, not news.
Koninklijke Philips N.V. makes MRI scanners that can guide surgery in real time — meaning a surgeon can operate while the magnet is running and watch what is happening on the scan, something standard MRI hardware cannot do because ordinary surgical tools scramble the magnetic field that produces a usable image. Philips solved that by designing a specific bore geometry with electromagnetic shielding precise enough to keep the field stable around an instrument, and because the shielding, the superconducting magnet winding, and the cryogenic qualification tests at its facility in Best, Netherlands all depend on each other, a competitor cannot copy just the shielding without rebuilding the entire system from scratch and then rerunning the multi-year regulatory submissions that Philips has already cleared with the FDA and CE authorities. That regulatory lock-in is what makes the revenue model work: hospitals that buy the capital equipment also need mandatory helium replenishment, cooling-system service contracts, and per-procedure software licenses, and switching to a different vendor would cost millions in new cryogenic infrastructure plus six months of staff retraining. The risk is that if European MDR regulators decide the bore-and-shielding combination constitutes a substantial change requiring a new conformity assessment, the CE marking lapses during resubmission — and without that clearance, hospitals cannot legally run the image-guided procedures the entire business is built around.
How does this company make money?
The company sells MRI scanners as large capital purchases, with hospitals typically replacing them every seven to ten years. On top of that, it charges recurring fees for cryogenic maintenance and software updates through service contracts. It also collects a fee each time a hospital uses the image-guided therapy software for a procedure, so revenue continues to flow between scanner purchases.
What makes this company hard to replace?
Connecting a new vendor's scanner to a hospital's existing information systems through DICOM takes six to twelve months of validation work. Radiologists and surgical teams need three to six months of training per facility before they can use a different system's image-guided workflows. The cryogenic infrastructure and magnet installations already in place represent switching costs in the millions of dollars.
What limits this company?
The scanner can only run as many procedures as the helium supply and maintenance schedule allow — not as many as hospitals actually want. Helium comes from a small number of natural-gas extraction sites, and any disruption to that supply can force a scanner offline. Even without a disruption, re-cooling and re-calibrating a magnet after a failure takes days, which means clinical demand alone cannot push throughput higher.
What does this company depend on?
The company cannot run without specialty suppliers of superconducting niobium-titanium wire for the magnet, liquid helium suppliers for continuous cryogenic cooling, FDA 510(k) clearances authorising image-guided therapy devices in the US, CE marking approvals allowing sales in Europe, and DICOM protocol licensing that lets the scanner communicate with hospital information systems.
Who depends on this company?
Academic medical centers use the system for complex neurosurgery and cardiac procedures — if the company stopped, those hospitals would lose real-time surgical navigation for their most difficult cases. Hospital radiology departments that have combined diagnostic and therapeutic workflows would face disruption across both functions. Sleep disorder clinics connected to the company's respiratory monitoring systems would lose patient data streams.
How does this company scale?
Image-processing software and patient-monitoring protocols can be pushed to every installed scanner at almost no extra cost once written. What does not get easier as the company grows is building the scanners themselves — winding the superconducting magnet, assembling the shielding geometry, and running cryogenic qualification tests all require highly trained technicians and cannot be meaningfully automated.
What external forces can significantly affect this company?
European MDR is forcing the company to re-submit clinical evidence for products already on the market, which consumes time and regulatory resources. Helium supply is vulnerable to geopolitical tensions around Qatar and Algeria, the main natural-gas extraction sites where helium is sourced as a byproduct. EU healthcare digitization rules are pushing hospitals to demand interoperability standards that may force the company to change how its systems connect with other hospital software.
Where is this company structurally vulnerable?
European MDR requires companies to re-submit clinical evidence for existing products on a set timetable. If regulators decide the bore-and-shielding design counts as a substantial change and demand a new conformity assessment, the CE marking that covers intraoperative MRI guidance could lapse during that re-submission — hospitals would have to suspend image-guided procedures on already-installed systems, and the regulatory barrier keeping competitors out of the same cleared geometry would disappear.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Net profit margin is positive while depreciation is a meaningful share of operating cash flow. The composition note: a non-trivial part of the earnings-to-cash bridge is depreciation specifically.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph